Biotech's use of AI still faces limitations, but a string of recent AI and biotech deals is fueling market enthusiasm and influencing Bessemer Venture Partners' investment strategy, says Andrew Hedin, a partner at the firm.
Catch up quick: Bessemer co-led a $120 million Series B in December for molecular glue degrader maker Triana Biomedicines, and participated in a $200 million Series A raised by RNA biotech Soufflé Therapeutics in October.
